Abstract: Objective To evaluate the efficacy and adverse reaction of neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in triple negative breast cancer （TNBC）. Methods Thirty TNBC patients accepted neoadjuvant chemotherapy with docetaxel and lobaplatin（docetaxel 75mg/m2 iv, d1; lobaplatin 30mg/m2 iv, d1; 21 days was a cycle）. The objective response and side effects were evaluated by WHO standard or histopathological reaction after surgery. Results Eight patients finished chemotherapy for 2 cycles， 17 patients for 4 cycles and 5 patients for 6 cycles. All patients were evaluable， 9 cases got CR， 15 cases got PR， 4 cases had SD， 2 cases were PD. The clinical benefit rate was 80.0％. Six cases achieved pCR according to the histopathological detection after surgery. The main adverse reaction was myelosuppression，with grade 12 leukopenia in 17 cases， grade 34 leukopenia in 5 cases， grade 1-2 thrombocytopenia in 7 cases， grade 3-4 thrombocytopenia in 2 cases and grade 12 anemia in 6 cases. Nonhemotologic toxicities were modest and recoverable. Conclusion Neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in TNBC is effective and well tolerated，which gives us a new choice.